NEW YORK – After publishing promising early data, investigators from Washington University in St. Louis plan to further validate the use of liquid biopsy-based minimal residual disease detection in oligometastatic colorectal cancer patients — individuals with cancers that have begun to seed new lesions in a small number of nearby sites but not yet widely through the whole body.
Liquid Biopsy MRD Detection Eyed as Decision Tool for Oligometastatic Colorectal Cancer Patients
Premium
Get the full story with
Premium Access
Only $95 for the
first 90 days*
Premium Access gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives
Never miss another important industry story.
You may already have institutional access!
Already a Precision Oncology News or 360Dx or GenomeWeb Premium member?
Login Now.
*Before your trial expires, we’ll put together a custom quote with your long-term premium options.
Not ready for premium?
Register for Free ContentYou can still register for access to our free content.